BioCentury
ARTICLE | Clinical News

SP-333: Phase I data

January 7, 2013 8:00 AM UTC

Top-line data from a placebo-controlled, dose-escalation, U.S. Phase I trial in about 56 healthy volunteers showed that single doses of SP-333 ranging from 0.1-60 mg did not produce any serious or une...